Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.27) by 22.22 percent. This is a 12.5 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $1.001 million which missed the analyst consensus estimate of $1.046 million by 4.33 percent. This is a 124.44 percent increase over sales of $446.000 thousand the same period last year.